Genelux

Genelux ROA

The Return on Assets (ROA) of Genelux (GNLX) as of Oct 27, 2026 is -168.94 %. In the previous year, Return on Assets (ROA) was -86.04 % — a change of 96.36% (lower).

ROA

-168.94 %

YoY

96.36%

Last updated:

In 2025, Genelux's return on assets (ROA) was -168.94 %, a 96.36% increase from the -86.04 % ROA in the previous year.

The Genelux ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-354.50 USD
Jan 1, 2020
-106.11 USD
Jan 1, 2021
-218.99 USD
Jan 1, 2022
-94.14 USD
Jan 1, 2023
-101.45 USD
Jan 1, 2024
-86.04 USD
Jan 1, 2025
-168.94 USD
The Genelux ROA history
YEARROAYoY
-168.94 %+96.36%
-86.04 %-15.19%
-101.45 %+7.76%
-94.14 %-57.01%
-218.99 %+106.38%
-106.11 %-70.07%
-354.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genelux Stock analysis

What does Genelux do? Genelux Corp develops and markets oncolytic viral immunotherapies, including Olvi-Vec, a modified vaccinia virus strain for platinum-resistant ovarian cancer, and V2ACT, a personalized anti-cancer therapy enhancing T cell activity. The company focuses on Phase II trials for Olvi-Vec in solid tumors and offers V-VET1, a veterinary oncolytic virus for animal health. Products target patients with solid tumor types and animal health applications, with clinical development driven by the firm's pipeline. The company generates revenue through the development and commercialization of its drug candidates, including Olvi-Vec, V2ACT, and V-VET1, targeting both human oncology and veterinary markets. Clinical trial phases and product development stages define its current focus, with Olvi-Vec in Phase II for ovarian cancer and V-VET1 in veterinary applications. The firm operates with a 15-employee structure, emphasizing pipeline advancement without publicized commercial sales yet. Genelux Corp's product portfolio includes Olvi-Vec for human solid tumors, V2ACT as a personalized immunotherapy, and V-VET1 for animal health. The company's revenue model relies on advancing these therapies through clinical trials, with no current commercial sales disclosed. The firm is positioned to address unmet needs in oncology, particularly in platinum-resistant cancers, and veterinary oncology through its viral-based approaches. Genelux is one of the most popular companies on Eulerpool.

ROA Details

Understanding Genelux's Return on Assets (ROA)

Genelux's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Genelux's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Genelux's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Genelux’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Genelux stock

Return on Assets (ROA) of Genelux is -168.94 % in 2025.

Return on Assets (ROA) of Genelux changed from -86.04 % to -168.94 %, representing a 96.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Genelux since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Genelux with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genelux

All Key Metrics — Genelux